MedPath

Assessment of Cardiac Sparing in Fetal Hypoxia

Not Applicable
Completed
Conditions
Fetal Hypoxia
Interventions
Radiation: Ultrasound
Radiation: Doppler ultrasound
Radiation: Fetal echocardiography
Registration Number
NCT03146507
Lead Sponsor
Assiut University
Brief Summary

The fetal heart plays a central role in the adaptive mechanisms for hypoxemia and placental insufficiency. Longitudinal data on the hemodynamic sequence of the natural history of fetal growth restriction show that the umbilical artery and middle cerebral artery are the first variables to become abnormal . These arterial Doppler abnormalities are followed by abnormalities in the right cardiac diastolic indices, followed by the right cardiac systolic indices, and finally by both left diastolic and systolic cardiac indices .

Preserving the left systolic function as the last variable to become abnormal ensures an adequate left ventricular output , which supplies the cerebral and coronary circulations.This defence is contingent on the fetal cardiovascular system, which in late gestation adopts strategies to decrease oxygen consumption and redistribute the cardiac output away from peripheral vascular beds and towards essential circulations, such as those perfusing the brain.

Adding cardiac Doppler may improve management of the IUGR fetus(intrauterine growth retardation), Doppler ultrasound is valuable in defining the degree of cardiovascular compromise in at-risk pregnancies. The severity of fetal blood flow redistribution shows the degree of fetal adaptation and provides information on how long the pregnancy can be continued safely.

The aime of the study is assessment of cardiac output redistribution in fetal hypoxia by estimating relative right to left side cardiac output wich reflect cardiac sparing in (IUGR).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
210
Inclusion Criteria
  1. Women aged 20-35 years.
  2. Women with BMI from 20-30 kg/m2.
  3. Pregnant women in singleton fetuses from 32 to 34 weeks gestation.
  4. Women with late fetal growth restriction fetuses. It refers to an estimated fetal weight or abdominal circumference <10th centile. Those women had increased the resistant index (RI) in umbilical arteries above the 95th percentile at the time of recruitment (case group).
  5. Normal pregnant women (control group).
Exclusion Criteria
  1. Women with estimated fetal weight below the 5th or 3rd percentile.
  2. Women with premature pre-labor rupture of membranes.
  3. Women with antepartum hemorrhage
  4. Women with fetal congenital anomalies.
  5. Women with absent or reversed diastolic flow in the umbilical artery at the time of recruitment.
  6. Women with preeclampsia or on anti-coagulant thereby.
  7. Women who refused to participate in our study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intrauterine growth restriction at 32-34 weeks groupDoppler ultrasound-
Intrauterine growth restriction at 32-34 weeks groupFetal echocardiography-
Normal pregnant women at 32-34 weeks groupUltrasound-
Normal pregnant women at 32-34 weeks groupFetal echocardiography-
Normal pregnant women at 32-34 weeks groupDoppler ultrasound-
Intrauterine growth restriction at 32-34 weeks groupUltrasound-
Primary Outcome Measures
NameTimeMethod
The relative cardiac output ratio (ratio between right side cardiac outputs to left side) cardiac output) at 32-34 weeks.1 month
Secondary Outcome Measures
NameTimeMethod
The relative cardiac output ratio at 34-36 weeks.1 month
The pulsatility index in the umbilical artery and middle cerebral artery at 32-34 weeks1 month
The pulsatility index in the umbilical artery and middle cerebral artery at 34-36 weeks1 month
Middle cerebral artery pulsatility index to umbilical artery pulsatility index ratio15 minutes
Time of delivery (weeks)7 weeks
Birth weight (grams)7 weeks

Trial Locations

Locations (1)

Advanced Fetal Cair Unit - Assiut University

🇪🇬

Assiut, Egypt

© Copyright 2025. All Rights Reserved by MedPath